medigraphic.com

2022, Number 4

<< Back Next >>

Med Crit 2022; 36 (4)

Relationship of lung distention pressure with mortality in patients under mechanical ventilation with COVID-19

Ríos JF, Soriano RS, Villarreal RE

Language: Spanish
References: 24
Page: 223-227
PDF size: 183.61 Kb.


ABSTRACT

Objective: To determine the relationship of driving pressure (DP) with mortality in patients under mechanical ventilation (MV) with COVID-19. Material and methods: Cohort study in patients with COVID-19 and MV from March to September 2020, two groups were compared, exposed (patients with DP greater than 13 cmH2O) and unexposed (patients with DP equal to or less than 13 cmH2O), age was analyzed, sex, hypertension (HT), diabetes, obesity, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), immunosuppression, and cardiovascular disease. Results: With a total of 90 patients, high DP was shown to be a risk factor for death (p = 0.000) as well as hypertension (p = 0.013) and immunosuppression (p = 0.040). In hypertensive patients, a DP of 10 cmH2O was found as a lung protection goal, which is related to the probability of dying in 49.6%, increasing to 89.6% when there is a DP of 13 cmH2O. Conclusions: 80% of the population has a high risk of mortality when there is high DP, and an increase in mortality when associated with hypertension and immunosuppression. The most important result was the mortality ratio of DP in hypertensive patients.


REFERENCES

  1. Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome?: a multicenter prospective observational study. Lancet Respir Med. 2020;8:1201-1208.

  2. COVID-19 situation update worldwide, as of week 10, updated 18 March 2021. European Centre for Disease Prevention and Control.

  3. Rello J, Storti E, Belliato M, et al. Clinical phenothypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020;55:2001028.

  4. Wang K, Zhao W, Li J, et al. The experience of high–flow nasal cannula in hospitalized patients with 2019 novel coronavirus – infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020;10(1):37.

  5. Pérez O, Zamarrón E, Soriano R, et al. Síndrome de distrés respiratorio agudo: abordaje basado en evidencia. Intensive Qare. 2019:1-16.

  6. Entenssoro E, Dubin A. Síndrome de distrés respiratorio agudo. Medicina (B. Aires). 2016;76:235-241.

  7. Carrillo-Esper R, de la Torre-León T, Carrillo-Córdova C, et al. Actividades en la definición, fisiopatología y tratamiento de la lesión pulmonar aguda. Med Int Méx. 2015;31:578-589.

  8. Pérez-Nieto OR, Deloya-Tomás E, Lomelí-Terán JM, et al. Presión de distensión (driving pressure): principal objetivo para la protección alveolar. Neumol Cir Torax. 2018;77(3):222-227.

  9. Amato M, Meade M, Slutsky A, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747-755.

  10. Amato M, Valente C, Machado D, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998; 338: 347-354.

  11. Gattinoni L, Pesenti A. The concept of "baby lung". Intensive Care Med. 2005;31:776-784.

  12. Bellani G, Laffey J, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in Intensive Care Units in 50 countries. JAMA. 2016;315(8):788-800.

  13. Slutsky AS, Ranieri M. Ventilator-induced lung injury. New Engl J Med. 2013;369:2126-2136.

  14. Arnal JM, Saoli M, Garnero A. Airway transpulmonary driving pressure and mechanical spowers selected by INTELLiVENT-ASV in passive, mechanically ventilated UCI patients. Heart Lung. 2020;49(4):427-434.

  15. García C, Bell-Castillo J, Romero-Calzado D, et al. La COVID-19 en personas hipertensas. MEDISAN. 2020;24(3):501-14.

  16. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristic of patients dying in relation to COVID-19. JAMA. 2020;323(18):1775-1776.

  17. Merad M, Martin J. Pathological inflammation in patients with COVID-19: a key role formonocytes and macrophages. Nat Rev Immunol. 2020;20:355-362.

  18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506.

  19. Fajgenbaum D, June C. Cytokine storm. N Engl J Med. 2020;383:2255-2273.

  20. Zirui M, Meng C, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.

  21. Cajamarca-Baron J, Guavita-Navarro D, Buitrago-Bhorquez J, et al. SARS-CoV-2 (COVID-19) en pacientes con algún grado de inmunosupresión. Reumatol Clin. 2021;17(7):408-419.

  22. Nájera H, Ortega-Ávila AG. Health and institutional risk factors of COVID-19 mortality in Mexico, 2020. Am J Prev Med. 2021;60(4):471-477.

  23. Lozano R, Gómez-Dante H, Garrido-Latorre F, et al. La carga de enfermedad, lesiones, factores de riesgo y desafíos para el sistema de salud en México. Salud Publica d México. 2012;6(55):280-594.

  24. Petrova D, Salamanca-Fernández E, Rodríguez M, et al. La obesidad como factor de riesgo en personas con COVID-19: posibles mecanismos e implicaciones. Aten Primaria. 2020;52(7):496-500.




2020     |     www.medigraphic.com